- Home
- NRXS vs XTNT Comparison
NRXS vs XTNT Comparison
Compare NRXS & XTNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NRXS | XTNT |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.9M | 68.9M |
| IPO Year | 2023 | 2009 |
Fundamental Metrics
Financial Performance| Metric | NRXS | XTNT |
|---|---|---|
| Price | $7.43 | $0.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $13.00 | $1.00 |
| AVG Volume (30 Days) | ★ 177.3K | 132.6K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 22.13 | ★ 125.00 |
| EPS | N/A | ★ N/A |
| Revenue | $3,569,282.00 | ★ $53,337,000.00 |
| Revenue This Year | $172.91 | N/A |
| Revenue Next Year | $115.71 | $9.30 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 32.89 | N/A |
| 52 Week Low | $2.20 | $0.44 |
| 52 Week High | $9.33 | $0.95 |
Technical Indicators
Market Signals| Indicator | NRXS | XTNT |
|---|---|---|
| Relative Strength Index (RSI) | 44.43 | 40.22 |
| Support Level | $6.80 | $0.44 |
| Resistance Level | $8.03 | $0.68 |
| Average True Range (ATR) | 0.63 | 0.03 |
| MACD | -0.16 | -0.01 |
| Stochastic Oscillator | 8.97 | 22.57 |
Price Performance
Historical ComparisonAbout NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
About XTNT Xtant Medical Holdings Inc.
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.